HCLTech launches suite of technology solutions for 5G and beyond
HCLTech, a leading global technology company, launched a range of innovative technology solutions for the 5G ecosystem at the Mobile World Congress 2023.
HCLTech’s solutions leverage its differentiated portfolio across digital, engineering, cloud and software to help communication service providers (CSPs) and enterprises supercharge their 5G readiness and accelerate monetization of their investments.
5G system integration framework (5G SF)
HCLTech’s 5G SF enables operators of public and private 5G to seamlessly deploy and integrate critical components of a future-ready network. With HCLTech’s 5G SF, CSPs, enterprises, hyperscalers, chip and equipment manufacturers will benefit from seamless virtual functions onboarding, significant operational efficiencies and enhanced network and user experiences.
“Communication service providers and enterprises need a system integration partner that can scale in diverse technology domains to integrate, deploy and operate 5G networks. With our 5G system integration framework, we have created a differentiated set of services to address the unique system integration requirements for disaggregated and distributed network domains that include RAN, transport and core,” said Vijay Guntur, President and Head, Engineering and R&D Services, HCLTech.
According to Jagdeshwar Gattu, President, Digital Foundation Services, HCLTech: “HCLTech’s heritage in architecture and design, system integration and management of complex networks across different technologies makes us a perfect partner for CSPs and enterprises aiming to achieving business outcomes by deploying industry-specific 5G use cases.”
CloudSMART Modernization Experience and Site Reliability Engineering (SRE)
With the onset of 5G, the CSPs are looking to rapidly transition from proprietary platforms to Cloud Native platforms, which provide flexibility and scalability to deliver customized services to users.
HCLTech’s innovative CloudSMART Modernization Experience for telecom supports the adoption of open-source and off-the-shelf IT vendor solutions. This gives telecom service providers the flexibility of developing tailored solutions by combining best-of-breed platforms from multiple network solutions providers.
HCLTech’s SRE enablement for Cloud Native telecom enables a complete set of practices required to successfully run telecom operations at scale using modern Cloud Native platforms. It allows telecom service providers to improve and maintain industry-best reliability levels through implementing advanced SRE practices within their operations, ultimately gaining efficiencies while reducing lock-in with traditional telecom network providers.
“We are thrilled to be launching these two new services to transform the ways in which enterprises across industries view their strategies for business growth and development,” said Kalyan Kumar, Chief Technology Officer, Head of Ecosystems and Chief Product Officer, Products and Platforms, HCLTech. “Our enablement of Cloud Native telecommunications platforms will provide a much-needed solution for businesses looking to take advantage of the latest advancements in the telecommunications industry.”
Ecosystem collaboration for network modernization
HCLTech in collaboration with Dell Technologies will provide network modernization solutions to CSPs and enterprises. HCLTech will provide end-to-end system integration services for vRAN (virtualized radio access networks), ORAN (open radio access networks), private 5G networks and edge/multi-access edge computing deployments, including telecom network transformation, design, interoperability, optimization and managed services. Dell Technologies will help CSPs modernize their network infrastructure to transform service delivery and simplify operations by performing platform integration services, including implementing engineered telecom cloud platforms, testing, automation and orchestration. Dell will also provide carrier-grade support and managed services designed for telecom operators and enterprises.
Learn more at https://www.hcltech.com/events/mwc-barcelona
About HCLTech
HCLTech is a global technology company, home to 222,000+ people across 60 countries, delivering industry-leading capabilities centered around digital, engineering and cloud, powered by a broad portfolio of technology services and products. We work with clients across all major verticals, providing industry solutions for Financial Services, Manufacturing, Life Sciences and Healthcare, Technology and Services, Telecom and Media, Retail and CPG and Public Services. Consolidated revenues as of 12 months ending December 2022 totaled $12.3 billion. To learn how we can supercharge progress for you, visit hcltech.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230227005461/en/
Contact information
Americas
Michelle Rico michelle.rico@hcl.com
EMEA
Elka Ghudial elka.ghudial@hcl.com
ANZ
James Galvin james.galvin@hcl.com
India and APAC
Devneeta Pahuja devneeta.p@hcl.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
ReNAgade Therapeutics Continues Commitment to GanNA Bio and Glycan Biology27.4.2024 03:09:00 EEST | Press release
ReNAgade Therapeutics, a company unlocking the limitless potential for RNA medicines, today announced its ongoing commitment to exploring the therapeutic opportunity of glycobiology through support for ongoing research at GanNA Bio, and the integration of key individuals of GanNA Bio into the ReNAgade ecosystem. GanNA founders Carolyn Bertozzi, Ph.D., and Richard D. Cummings, Ph.D, will now serve as advisors to ReNAgade. “ReNAgade will continue to benefit tremendously from GanNA’s promising work in developing extra-hepatic delivery technology that helps expand the breadth and potential of our own RNA medicines,” said Brian Goodman, Co-founder of ReNAgade. “Delivery is foundational to ReNAgade’s mission to overcome the current limitations of RNA medicines. We believe the technology developed within GanNA will help further solidify ReNAgade’s leadership position as we continue advancing our unique, integrated therapeutic platform.” Formed in 2021 and invested in by ReNAgade, GanNA Bio ha
HCLTech Reports FY24 Revenue of $13.3 Billion, up 5.4% YoY26.4.2024 23:06:00 EEST | Press release
HCLTech, a leading global technology company, today reported financial results for the fourth quarter and the full year ended March 31, 2024. The company reported full year revenue of $13.3 billion, up 5.4% YoY. Digital Services revenue grew by 5.3% (CC) and now contributes to 37.3% of IT Services revenue. HCLSoftware’s Annual Recurring Revenue came in at $1.02 billion. During FY24, the company won 73 large deals – 36 in Services and 37 in Software - that translated into TCV (new deal wins) of $9.76 billion, up 10% YoY. For the quarter, revenue came in at $3.43 billion, up 6% YoY. HCLTech won 21 large deals – 13 in Services and eight in Software, with a TCV of $2.29 billion during the quarter. In terms of geographies, Americas was the fastest growing region with 6.8% YoY (CC) growth followed by Europe, which grew by 5.5% YoY (CC). Industry vertical growth was led by Financial Services and Telecommunications, Media, Publishing & Entertainment. While Financial Services grew at 12.1% YoY
Kinaxis Positioned Highest on Ability to Execute in the Gartner® Magic Quadrant™ for Supply Chain Planning Solutions26.4.2024 19:03:00 EEST | Press release
Kinaxis® Inc. (TSX:KXS), a global leader in end-to-end supply chain orchestration, today announced it has been named a Leader in the 2024 Gartner® Magic Quadrant™ for Supply Chain Planning Solutions. Of the 20 vendors evaluated, Gartner positioned Kinaxis highest on Ability to Execute, marking the company’s 10th consecutive Leaders Quadrant within the report, a complimentary copy of which can be downloaded here. Kinaxis attributes its position to its patented concurrency approach and a proven track record of delivering innovative solutions against the foundation of its leading vision through the use of advanced technology such as AI, ML, and an intuitive user experience. Bolstered by a rich ecosystem of third-party implementation partners, Kinaxis continues to demonstrate that regardless of a customer’s industry, size, or maturity level, the company can be counted on to seamlessly orchestrate supply chain networks end-to-end from strategic planning to last-mile delivery. The recognitio
Vertex Announces European Commission Approval for KALYDECO® to Treat Infants With Cystic Fibrosis Ages 1 Month and Older26.4.2024 18:43:00 EEST | Press release
Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that the European Commission has granted approval for the label expansion of KALYDECO® (ivacaftor) for the treatment of infants down to 1 month of age with cystic fibrosis (CF) who have one of the following mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene: R117H, G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N or S549R. “Today’s approval is an important milestone for the cystic fibrosis community. Treating CF early in life can potentially slow the progression of the disease, which is why it is so important to start treatment from a very young age,” said Carmen Bozic, M.D., Executive Vice President, Global Medicines Development and Medical Affairs, and Chief Medical Officer, Vertex. As a result of existing access agreements in Austria, Czech Republic, Denmark, Ireland, Norway, Sweden, and The Netherlands, eligible patients will have access to the expanded indication of KALYDECO® (ivacaftor)
Suzano 2023 annual report on Form 20-F26.4.2024 18:22:00 EEST | Press release
Suzano S.A. (B3: SUZB3 | NYSE: SUZ) informs that its 2023 Annual Report on Form 20-F was filed today with the U.S. Securities and Exchange Commission. Holders of the Company’s equity securities can receive hard copies of the Annual Report, including its audited financial statements, without charge by request directed to: ri@suzano.com.br. This document is also available on Suzano’s website (http://ir.suzano.com.br/). For further information, please contact our Investor Relations Department: Phone: (+55 11) 3503-9330 E-mail: ri@suzano.com.br View source version on businesswire.com: https://www.businesswire.com/news/home/20240426289818/en/ Contact information Hawthorn Advisors suzano@hawthornadvisors.com
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom